Renaissance Technologies LLC boosted its holdings in shares of Bio-Path Holdings Inc (NASDAQ:BPTH) by 45.3% in the 2nd quarter, Holdings Channel reports. The fund owned 198,730 shares of the company’s stock after buying an additional 62,000 shares during the quarter. Renaissance Technologies LLC’s holdings in Bio-Path were worth $296,000 at the end of the most recent quarter.

Separately, ValuEngine raised Bio-Path from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st.

BPTH stock opened at $0.45 on Friday. Bio-Path Holdings Inc has a 52-week low of $0.33 and a 52-week high of $3.30.

Bio-Path (NASDAQ:BPTH) last released its quarterly earnings results on Wednesday, August 15th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.05.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.dailypolitical.com/2018/11/10/bio-path-holdings-inc-bpth-holdings-raised-by-renaissance-technologies-llc.html.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Featured Article: How are Outstanding Shares Different from Authorized Shares?

Want to see what other hedge funds are holding BPTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Path Holdings Inc (NASDAQ:BPTH).

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.